ValtedSeq
Private Company
Funding information not available
Overview
ValtedSeq is a private, pre-clinical biotech company pioneering a data-driven approach to neurodegenerative diseases. Founded by renowned Johns Hopkins scientists Dr. Ted Dawson and Dr. Valina Dawson, the company's core asset is its HiF-Seq™ platform, which enables high-efficiency single-cell sequencing from frozen brain tissue to create an unprecedented data repository. This data fuels the discovery of novel therapeutic targets and the development of ultra-sensitive diagnostic assays, particularly targeting pathways like PAR and c-Abl. As a subsidiary of D&D Pharmatech/Neuraly, ValtedSeq is positioned to translate its foundational discoveries into clinical programs.
Technology Platform
Proprietary HiF-Seq™ platform for high-efficiency single-cell RNA sequencing from frozen post-mortem brain tissue sections, enabling creation of a massive genomic data repository for target and biomarker discovery.
Opportunities
Risk Factors
Competitive Landscape
ValtedSeq competes in a crowded space that includes large genomics firms (e.g., Illumina, 10x Genomics via their platforms), biopharma companies with internal genomics efforts, and other neuro-focused biotechs. Its differentiation lies in the specific application of its HiF-Seq™ technology to challenging post-mortem brain samples and its exclusive focus on building a proprietary, disease-specific data asset.